5-氨基乙酰丙酸荧光引导切除联合光动力治疗在复发胶质母细胞瘤中的匹配队列研究
该匹配队列研究比较复发胶质母细胞瘤患者接受5-ALA荧光引导切除联合术中光动力治疗(前瞻性11例)与单纯5-ALA荧光引导切除(历史性11例)的生存率和安全性,结果显示联合组生存率显著优于单纯组(p=0.008),两组术后并发症各4例(36.6%),作者认为联合治疗似乎与更好生存相关且不增加严重并发症。
要点
- 复发胶质母细胞瘤中,5-ALA荧光引导切除联合术中光动力治疗组生存率显著高于单纯5-ALA荧光引导切除组(p=0.008)。
核心结论
- 复发恶性胶质瘤中,5-ALA荧光引导切除后立即联合光动力治疗似乎与更好生存相关,且不增加额外或严重并发症。
- 作者认为该治疗是再次手术可行且安全的补充,但需要更大规模的随机系列研究。
研究设计与样本
- 匹配配对队列研究,两组复发胶质母细胞瘤患者均接受5-ALA荧光引导切除。
- 第1组为前瞻性连续11例接受5-ALA荧光引导切除联合术中光动力治疗。
- 第2组为历史性连续11例接受单纯5-ALA荧光引导切除。
- 记录年龄、性别、KPS、5-ALA切除后状态、T1增强切除范围、既往和术后病理、IDH、Ki67、既往和术后治疗、脑MRI对照和手术并发症。
主要发现
- Mantel-Cox检验显示两组生存率差异显著(p=0.008)。
- 每组发生4例术后并发症(36.6%)。
- 截至末次随访(2024年1月),第1组7/11例患者仍存活,第2组0/11例患者仍存活。
临床怎么用
- 作者认为,对于复发恶性胶质瘤,5-ALA荧光引导切除后立即联合光动力治疗似乎是再次手术可行且安全的补充。
局限性
- 原文指出需要更大规模的随机系列研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma is a malignant and aggressive brain tumour that, although there have been improvements in the first line treatment, there is still no consensus regarding the best standard of care (SOC) upon its inevitable recurrence. There are novel adjuvant therapies that aim to improve local disease control. Nowadays, the association of intraoperative photodynamic therapy (PDT) immediately after a 5-aminolevulinic acid (5-ALA) fluorescence-guided resection (FGR) in malignant gliomas surgery has emerged as a potential and feasible strategy to increase the extent of safe resection and destroy residual tumour in the surgical cavity borders, respectively. OBJECTIVES: To assess the survival rates and safety of the association of intraoperative PDT with 5-ALA FGR, in comparison with a 5-ALA FGR alone, in patients with recurrent glioblastoma. METHODS: This article describes a matched-pair cohort study with two groups of patients submitted to 5-ALA FGR for recurrent glioblastoma. Group 1 was a prospective series of 11 consecutive cases submitted to 5-ALA FGR plus intraoperative PDT; group 2 was a historical series of 11 consecutive cases submitted to 5-ALA FGR alone. Age, sex, Karnofsky performance scale (KPS), 5-ALA post-resection status, T1-contrast-enhanced extent of resection (EOR), previous and post pathology, IDH (Isocitrate dehydrogenase), Ki67, previous and post treatment, brain magnetic resonance imaging (MRI) controls and surgical complications were documented. RESULTS: The Mantel-Cox test showed a significant difference between the survival rates (p = 0.008) of both groups. 4 postoperative complications occurred (36.6%) in each group. As of the last follow-up (January 2024), 7/11 patients in group 1, and 0/11 patients in group 2 were still alive. 6- and 12-months post-treatment, a survival proportion of 71,59% and 57,27% is expected in group 1, versus 45,45% and 9,09% in group 2, respectively. 6 months post-treatment, a progression free survival (PFS) of 61,36% and 18,18% is expected in group 1 and group 2, respectively. CONCLUSION: The association of PDT immediately after 5-ALA FGR for recurrent malignant glioma seems to be associated with better survival without additional or severe morbidity. Despite the need for larger, randomized series, the proposed treatment is a feasible and safe addition to the reoperation.
引用
- da Silva EB, Vasquez MWM, de Almeida Teixeira BC, et al. Association of 5-aminolevulinic acid fluorescence guided resection with photodynamic therapy in recurrent glioblastoma: a matched cohort study. Acta Neurochir (Wien). 2024. PMID: 38739282. doi:10.1007/s00701-024-06108-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。